Drug Profile
Research programme: cystic fibrosis transmembrane conductance regulator modulators - Galapagos/AbbVie
Alternative Names: Cystic fibrosis therapy research programme - Cystic Fibrosis Foundation/Galapagos; GLPG-2665Latest Information Update: 27 Dec 2022
Price :
$50
*
At a glance
- Originator Cystic Fibrosis Foundation Therapeutics; Galapagos NV
- Developer AbbVie; Galapagos NV
- Class Small molecules
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cystic fibrosis
Most Recent Events
- 27 Dec 2022 Discontinued - Preclinical for Cystic fibrosis in Belgium (PO)
- 27 Dec 2022 Discontinued for Cystic fibrosis (Combination therapy) in Belgium (PO)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Cystic-fibrosis in Belgium (PO)